{"schema_version":"secwatch.filing_event.v1","accession":"0000947871-23-000898","form_type":"8-K","ticker":"CVS","cik":"0000064803","company_name":"CVS HEALTH Corp","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.411213+00:00","generated_at":"2026-06-11T05:06:30.977274+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CVS Health launches Cordavis subsidiary; first biosimilar Hyrimoz at >80% lower list price than Humira","bullets":["Launched Cordavis, a wholly owned subsidiary to commercialize and co-produce biosimilar products in the U.S.","First product: Cordavis private-label Hyrimoz (adalimumab-adaz) from Sandoz, launching Q1 2024.","List price of Cordavis Hyrimoz will be more than 80% lower than current Humira list price.","U.S. biosimilar market projected to grow from <$10B in 2022 to >$100B by 2029.","CVS CFO states Cordavis will help ensure sufficient biosimilar supply and reduce drug costs for consumers."],"urls":{"canonical":"https://secwatch.observer/filing/0000947871-23-000898","json":"https://secwatch.observer/filing/0000947871-23-000898.json","markdown":"https://secwatch.observer/filing/0000947871-23-000898.md","text":"https://secwatch.observer/filing/0000947871-23-000898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/64803/000094787123000898/0000947871-23-000898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64803/000094787123000898/ss2413675_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T05:06:30.977274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}